title: PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy.
abstract: Targeted therapy is gaining prominence in the management of different cancers. Given different mechanism of action compared with traditional chemoradiotherapy, selection of patients for targeted therapy and monitoring response to these agents is difficult with conventional imaging. Various new PET radiopharmaceuticals have been evaluated for molecular imaging of these targets to achieve specific patient selection and response monitoring. These PET/computed tomography (CT) agents target the cell surface receptors, hormone receptors, receptor tyrosine kinases, or angiogenesis components. This article reviews the established and potential role of PET/CT with new radiopharmaceuticals for guiding targeted therapy.
authors.affiliation: Department of Nuclear Medicine and PET/CT, Eastern Diagnostics India Ltd, 13C Mirza Ghalib Street, Kolkata 700016, India; Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
authors.forename: Punit
authors.initials: P
authors.lastname: Sharma
authors.affiliation: Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. Electronic address: rkphulia@yahoo.com.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
mesh_terms: D006801:Humans; D007089:Image Enhancement / Q000379:methods; D058990:Molecular Targeted Therapy / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals
keywords: Angiogenesis; Hormone receptor; PET/CT; Prostate-specific membrane antigen; Radiopharmaceutical; Somatostatin receptor; Targeted therapy; Tyrosine kinase